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2Summary
•  The NICE Guideline on Depression in Adults makes clear the complex nature of 
depression and its clinical and social importance.
•  It highlights the important role of psychological therapies in the treatment of 
depressive disorders.
•  It recognises the importance of maintaining a plurality of treatment and not 
withdrawing established psychotherapies.
•  The scope of the guideline is limited by a narrow, undifferentiated and simplistic 
conception of depression. It unhelpfully restricts itself to randomised controlled 
trials, and excludes naturalistic trials despite their advantages in assessing 
psychotherapeutic treatments and treatments in the real world. 
•  The evidence of the lasting effects of long-term psychotherapy in depression is not 
reviewed despite the evidence that depression is frequently chronic or recurring 
and the evidence of the limited effect of short-term treatments. 
•  The guideline fails to consider the importance of individual patient preferences or 
different types of depression, leading to restrictive and misleading one-size-fits-all 
recommendations.
•  The evidence presented, in keeping with the scientific literature, demonstrates 
equivalence between Cognitive Behavioural, Interpersonal, and Short Term 
Psychodynamic Psychotherapies.
•  The guideline misleads by recommending CBT based on the number of studies 
supporting it. 
•  CBT for depression provided through the Improving Access to Psychological 
Therapies services has not to date shown itself more effective or acceptable to 
patients in the real world than non-CBT therapies.
•  There is an urgent need for well-funded trials to explore if those who do not 
respond to CBT can benefit from other forms of treatment including psychodynamic 
psychotherapy and the extent to which long-term treatments have superior 
outcomes in the medium or long-term.
The National Institute for Health and Clinical Excellence (NICE) this year updated 
the NICE clinical guideline for the treatment of depression in adults. The British 
Psychoanalytic Council, Association for Psychoanalytic Psychotherapy in the NHS, 
Anna Freud Centre, and Tavistock and Portman NHS Foundation Trust as a group 
contributed to the consultation, cautiously welcoming the draft, but disagreed with 
the way that NICE had assembled its evidence, favouring CBT at the expense of 
other psychological therapies.
3The National Institute for Health and 
Clinical Excellence (NICE) is an independent 
organisation responsible for providing 
national guidance on promoting good 
health and preventing and treating ill 
health. It publishes guidance which aims 
to ensure that the promotion of good 
health and patient care in local health 
communities is in line with the best 
available evidence of effectiveness and  
cost effectiveness.
In 2004 NICE published Clinical Guideline 
23 on Depression: management of 
depression in primary and secondary 
care, as a full guideline and a condensed 
NICE clinical guideline (NICE, 2004). 
NICE has published a separate guideline 
on Depression in Children and Young 
People (NICE 2005). Further guidelines on 
Depression in Chronic Health Problems and 
Anxiety and Depression are in progress.
As part of a planned updating process 
in February 2009 NICE published draft 
revisions of the full guideline (NICE, 2009a) 
and condensed clinical guideline (NICE, 
2009b). NICE has now published its partial 
update, Clinical Guideline 90 (NICE 2009c, 
d, e). 
The revision rightly emphasises the complex 
nature of depression and its importance, 
highlighting the central importance of 
psychological therapies in the treatment of 
depressive disorders:
•  That depression is a ‘heterogeneous group 
of related disorders’ (NICE 2009c, p13)
•  That ‘incomplete recovery and relapse are 
common’ (p15).
•  That when depression persists or recurs 
after treatment it is important to consider 
which ‘psychosocial factors may be 
preventing recovery’ (p16)
•  That ‘the impact [of depression] on social 
and occupational functioning, physical 
health and mortality is substantial’ (p17). 
•  ‘Emotional, motivational and cognitive 
effects substantially reduce a person’s 
ability to work effectively, with losses in 
personal and family income as well as lost 
contribution to society in tax revenues and 
employment skills. Wider social effects 
include: greater dependence upon welfare 
and benefits with loss of self-esteem 
and self-confidence; social impairments, 
including reduced ability to communicate 
and sustain relationships during the illness 
with knock-on effects after an episode; 
and longer term impairment in social 
functioning, especially for those who have 
chronic or recurrent disorders’ (p17).
•  ‘Depressive illness causes a greater 
decrement in health state than the major 
chronic physical illnesses angina, arthritis, 
asthma, and diabetes’ (p17)
•  ‘Nearly two-thirds of [suicides] occur in 
depressed people’ (p17). 
•  ‘Marital and family relationships are 
frequently negatively affected, and parental 
depression may lead to neglect of children 
and significant disturbances in children’ 
(p17).
•  That depression has important social 
origins (p18). 
•  That subthreshold depression is of great 
importance (p18).
•  ‘Early life experiences such as a poor 
parent–child relationship, marital discord 
and divorce, neglect, physical abuse and 
sexual abuse almost certainly increase a 
person’s vulnerability to depression in later 
life (p21). 
•  ‘Personality traits such as ‘neuroticism’ 
also increase the risk of depression when 
faced with stressful life events’ (p21).
•  ‘The role of current social circumstances 
in increasing the risk of depression, such as 
poverty, homelessness, unemployment and 
chronic physical or mental illness cannot 
be doubted even from a brief examination 
of the epidemiology of depression… social 
vulnerability factors for depression in 
4women in Camberwell, South-East London, 
included: having three or more children 
under the age of 14 years living at home; 
not having a confiding relationship with 
another person; and having no paid 
employment outside the home. Lack of 
a confiding relationship appears to be a 
strong risk factor for depression’ (p21).
•  ‘Less than half of treated patients 
achieved full remission and sustain it over 
a period of 2 years following treatment’ 
(p142).
The guideline emphasises the complex 
nature of treatment decisions and the 
limitations of the evidence base for the 
psychotherapeutic treatment of depression,
•  …symptom counting … and … symptom 
severity rating scales by themselves 
should not be used to make the diagnosis, 
although they can be an aid in assessing 
severity and response to treatment. (p19).
•  That making ‘a diagnosis of depression 
does not automatically imply a specific 
treatment‘ (p20)
•  That ‘it is also common for depressed 
people to a have co-morbid psychiatric 
diagnosis, such as anxiety, social phobia, 
panic and various personality disorders, 
and physical co-morbidity’ (p20), to which 
one should add substance misuse
•  ‘Choice of treatment is a complex process 
and involves negotiation and discussion 
with patients, and, given the current 
limited knowledge about what factors are 
associated with better antidepressant or 
psychotherapy response, most decisions 
will rely upon clinical judgement and patient 
preference until we have further research 
evidence. Trials of treatment in unclear 
cases may be warranted but the uncertainty 
needs to be discussed with the patient and 
benefits from treatment carefully monitored’ 
(p20).
•  That ‘guidelines are not a substitute 
for professional knowledge and clinical 
judgement’ and that ‘there will always 
be some people and situations for which 
clinical guideline recommendations are 
not readily applicable. This guideline does 
not, therefore, override the individual 
responsibility of healthcare professionals 
to make appropriate decisions in the 
circumstances of the individual, in 
consultation with the person with 
depression or their carer’ (p9), and that ‘a 
good therapeutic relationship is at times 
as important as the specific treatments 
offered’ (p10).
The guideline recognises the importance of 
maintaining a plurality of treatment and not 
withdrawing established psychotherapies:
•  ‘Where established therapies are not 
recommended, this does not necessarily 
mean that the withdrawal of provision from 
the NHS is endorsed but may suggest the 
need for further research to establish their 
effectiveness or otherwise’ (p142).
However, the guideline and its proposed 
implementation through IAPT centres have 
been criticised by third sector mental health 
providers, psychoanalytic practitioners, 
and CBT researchers, as being flawed 
and unworkable. The Mental Health 
Providers Forum (MHPF 2009), for example, 
representing 36 third sector mental health 
providers, shared our concerns about the 
methodologies and limited range of studies 
used by NICE. 
5Misrepresentation of results
The guidelines recommend that high 
intensity psychological treatment for 
moderate depression should be CBT  or 
IPT (or in some circumstances behavioural 
activation or behavioural couples therapy). 
If antidepressants, CBT, IPT, behavioural 
activation or behavioural couples therapy 
have been declined then the guideline 
allows that:
‘short-term psychodynamic psychotherapy 
might still be considered… but that the 
limited evidence should be drawn to the 
attention of the healthcare professional 
[sic].’ (NICE 2009c p249-250). 
In the the Quick Reference Guide clinicians 
are instructed to: 
‘Discuss with the person the uncertainty 
of the effectiveness of counselling and 
psychodynamic psychotherapy in treating 
depression.’ (NICE 2009e p16)
The evidence presented in the Full Guidance 
demonstrates ‘no clinically important 
differences’ between cognitive behavioural 
therapy, interpersonal psychotherapy, short-
term psychodynamic psychotherapy and 
brief supportive counselling, behavioural 
activation or GP treatment as usual. (NICE, 
2009c, Full Guidance p199-200).
‘The evidence indicates no clinically 
important differences for the comparison 
of CBT with short-term psychodynamic 
psychotherapy in decreasing depression 
(BDI at endpoint SMD -0.35; 95% CI -1.30, 
0.61) or with Gestalt psychotherapy (BDI at 
endpoint SMD 0.17; 95%-0.56, 0.91). From 
this evidence it is not possible to draw any 
clear conclusions about the relative efficacy 
of the treatments.’ (p198-199) 
‘Again, there were no clinically important 
differences between CBT and IPT (BDI at 
endpoint 0.21; 95% CI -0.01, 0.41; HRSD 
at endpoint 0.13; 95% CI -0.06, 0.32). 
This evidence although limited suggests 
that IPT might be as effective as CBT in the 
treatment of depression.’ (p198) 
‘There were no clinically important 
differences identified between CBT and 
behavioural activation (BDI at endpoint 
0.34; 95% CI -0.26, 0.95; HRSD at endpoint 
-0.03; 95% CI -0.62, 0.57). From this 
evidence it is not possible to draw any clear 
conclusions about the relative efficacy of 
the treatments.’ (p198) 
‘Three trials reported in the previous 
guideline included a comparison between 
CBT in primary care versus usual GP care. The 
studies varied in duration: Freeman2002 
consisted of 16 sessions over a 5-month 
period, Scott1992 was of 16-week duration 
and Scott1997 was of 6 weeks. In terms of 
leaving the study early due to any reason, 
the evidence suggests that there is a 
higher risk for discontinuation in those 
in the CBT (primary care) group (RR 1.54; 
95% CI 0.97 to 2.46). The evidence here 
is difficult to interpret as many patients in 
GP care may have been in receipt of anti-
depressants and the duration of treatment 
was shorter than that typical of CBT. At 
end of treatment self-report depression 
scores SMD 0.01 (-0.83 to 0.85) were not 
significantly different as were clinician 
rated depression scores SMD -0.33 95% CI 
(-0.74 to 0.08).’ (p199)  
It is important to note that the evidence 
base for STPP is extensive, far more 
extensive than the limited number of studies 
included in NICE’s review of the evidence, 
but that many trials of STPP were excluded 
on questionable grounds (see below). 
In this respect the analysis is consistent 
with other large meta-analyses. E.g. 
Cuijpers et al. (2008) analysed 53 RCTs and 
concluded that all short-term psychological 
therapies were equally efficacious with 
the exception of IPT, which was marginally 
6more efficient and non-directive supportive 
treatment was marginally less effective. 
The authors concluded that there was no 
large difference in the efficiency between 
the major psychotherapies for mild to 
moderate depression. The authors also 
reviewed earlier comparisons of CBT and 
other short-term psychotherapies and found 
no evidence of difference after controlling of 
investigator allegiance. The guideline cites 
Elkin (1989) as also finding no difference 
between CBT and IPT, however this is a 
misrepresentation, the study reported that 
‘Comparing each of the psychotherapies 
with the placebo plus clinical management 
condition, there was limited evidence of 
the specific effectiveness of interpersonal 
psychotherapy and none for cognitive 
behavior [sic] therapy.’ (p971). However 
other studies do report finding no evidence 
of differences between different short-
term psychotherapies: Wampold et al. 
(1997), Robinson et al. (1990), Churchill 
et al. (2001) found that less severely 
affected individuals (self-selected patients 
and volunteers) appeared to benefit 
more from CBT, but that among the more 
severely affected (individuals attending 
psychiatric outpatients and the more 
severely depressed) there was no difference 
between groups.
The evidence reviewed by NICE provides 
support for the ‘equivalence paradox’ that 
different short-term psychotherapies are 
equally effective, at a global level and 
in the short-term, in a range of neurotic 
conditions. The equivalence paradox has 
survived over thirty years (Cuijpers et al. 
2008) and has recently been confirmed in 
a large outcome study in the NHS (Stiles et 
al 2008).
In moving from evidence to recommendations 
(section 8.9.8) the final guideline (NICE 
2009c) states ‘With 46 studies, cognitive 
behavioural therapies have the largest 
evidence base’ (p245). Later this becomes: 
‘CBT has the best evidence base for efficacy 
but it is not effective for everyone’ (p253). In 
commenting on the decision to withdraw the 
previous recommendation for psychodynamic 
therapy, the draft guideline comments that 
the decision ‘was influenced by contextual 
changes in the NHS including the significant 
increase in evidenced based psychological 
interventions [guided self help and CBT] made 
available through the IAPT [Improving Access 
to Psychological Therapies] programme’ 
(NICE 2009a, p196); this comment is 
dropped from the final version.
It is important not to confound number of 
trials with what the trials show. The purpose 
of systematic reviews is to carefully weigh 
up what the evidence actually shows, not 
simply count the trials and go with the most 
voluminous evidence. Evidence based 
recommendations should be based on what 
the trials show, not the number of trials. 
That the Guideline Development Group was 
influenced to drop the recommendation 
for psychodynamic psychotherapy on 
the grounds of the greater availability of 
guided self help and CBT through IAPT 
reveals circular thinking (we’ll recommend 
it because it’s available) and a disregard 
for scientific evidence that should have no 
place in an evidence based guideline. 
Saying that the evidence is limited, or 
uncertain, after a partial review of the 
evidence (see below), and a review that 
nonetheless found ‘no clinically important 
differences’, is misleading.
Through ‘vote counting’, misrepresenting 
the data, and circular thinking, 
recommendations are made which will be 
widely misinterpreted as showing that CBT 
and IPT are superior treatments, whereas 
in reality the guideline demonstrates ‘no 
clinically important differences’ between 
the short-term psychological therapies 
reviewed.  
7The problem of considering 
depression as a unitary disorder
Given that the complexity of depression 
has been thoroughly recognised in 
the preamble to the guideline it is 
inconsistent that the guideline goes on 
to treat depression as if it were a single 
homogeneous condition, distinguished 
only by degrees of severity, with the 
diagnosis based on symptom counts, and 
ignores the importance of social origins, 
co-morbidity, psychosocial factors that may 
prevent recovery, relationship difficulties or 
effects on children. The guideline does not 
adequately distinguish between depression 
as a symptom, syndrome, or the spectrum 
of neurotic and personality difficulties and 
disorders (McQueen in press).
The validity of the diagnosis of depression 
as a unitary concept is not supported by 
epidemiology, phenomenology or genetics 
(Cole et al. 2008). Depression and related 
neurotic conditions; generalised anxiety 
disorder and obsessive-compulsive 
disorder do not occur independently of each 
other. They do not have their own particular 
aetiology. They do not respond only to 
specific treatments acting on pathological 
processes specific to the presumed 
disorder. And they commonly change over 
time, with the features of depression, 
anxiety, phobic or obsessive-compulsive 
disorders alternating  (Goldberg & Goodyer, 
2005, Tyrer, 1985; Tyrer et al.  2003; 
Taylor, 2008). Most patients with clinically 
significant depression meet the criteria for 
several different symptom-based diagnoses 
and have to cope with many additional 
suboptimal functions of the personality 
(Westen et al, 2004). Only a minority satisfy 
the criteria of only one diagnosis: patients 
meeting criteria for major depressive 
disorder are nine times more likely than 
chance to meet the criteria for other 
conditions (Angst & Dobler-Mikola, 1984); 
50–90% of patients with Axis I conditions 
also meet the criteria for other Axis I or 
Axis II disorders (Westen et al, 2004). A 
large epidemiological study found that 
72.1% of a community sample of adults 
with depression had co-morbid axis I or II 
disorders; 59.2% had anxiety disorders, 
24.0% had substance use disorders, and 
30.0% had impulse control disorders 
(Kessler et al. 1993). Others have reported 
that 48% of those with depression have 
generalised anxiety disorder (GAD), and 
72% of those with GAD have depression 
(Moffitt et al. 2007). 
It follows from the lack of differentiation 
of depressive disorders in the guidance 
that there is no recognition that CBT may 
be counterproductive in some sub-types of 
depression (Casement, 2009). Personality 
disorders have been found to have a 
negative prognostic impact on depressive 
disorders (Gunderson et al, 2004; Shea et 
al, 1990). For example, the rate of remission 
of Mood Disorder is significantly reduced 
by co-occurring Borderline Personality 
Disorder (BPD) (Gunderson et al, 2004). 
Improvements in BPD will be more often 
followed by improvements in the Mood 
Disorder. For this reason it is recommended 
that clinicians should primarily treat the 
personality disorder (Gunderson et al, 
2004). 
Despite the recognition of the importance 
of diverse aetiological factors in the 
preamble (p20), these are lacking from 
the treatment guidance. An understanding 
of developmental psychopathology 
should inform the understanding and 
treatment of depression in adults (e.g., 
the special edition of Development and 
Psychopathology, 1992, vol. 4).  For some 
(perhaps many) individuals presenting with 
feelings of unhappiness, unworthiness, 
and so on, there is a need to promote 
8development through the maladaptive 
relationships and emotional difficulties with 
which they present (Balint, 1968; McQueen 
et al, 2008; Hall & Marzillier 2009).
Patients with depression who have 
experienced early relational trauma 
have differential responses to treatment 
for depression (Nemeroff et al, 2003) 
(and molecular and functional brain 
changes (McGowan et al, 2009). CBT 
and antidepressants may have at best 
limited contributions in this regard but the 
recommendations overlook these factors.
Individuals with a weaker sense of their 
own subjectivity, such as those who 
have received a diagnosis of borderline 
personality disorder, find it harder 
to compare the validity of their own 
perceptions of the way their mind works 
with the explanations and models that 
a ‘mind expert’ (clinician) offers. Both 
cognitively based and dynamically 
orientated therapies can give ready-
made answers and provide illusory 
stability by inducing a process of pseudo-
mentalisation in which the patient takes 
on the explanations without question and 
makes them his/her own. Conversely, both 
types of perspective can be summarily 
and angrily dismissed as overly simplistic 
and patronising, which in turn fuels 
a sense of abandonment, feelings of 
isolation and desperation (Fonagy & 
Bateman, 2006). Without reference to 
these potential complexities the guideline 
may inadvertently encourage simplistic 
formulations for treatment. 
A single disorder guideline for depression 
is clinically artificial and of questionable 
clinical use. 
The need for guidelines on the  
treatment of mixed disorders
In clinical practice most treatment-seeking 
patients with ‘depression’ have comorbid 
neurotic disorders, personality disorders, 
and or substance misuse. This, coupled 
with the questionable utility of depression 
as a unitary diagnosis, suggests the need 
for research and guidelines on how to treat 
the actual patients that seek treatment, 
with a range of complexity, comorbidity 
and aetiologically diverse conditions that 
feature depression. Trials using patients 
with ‘pure’ depression, or depression 
without comorbidity are unrepresentative 
and less unwell than patients with 
comorbidity, these patients are likely to 
have better outcomes because of their 
less severe conditions consequently trials 
with patients with ‘pure’ depression risk 
overstating the benefits of treatment.
The guideline refers to several systematic 
reviews and meta-analyses which show 
both that STPP is effective for mixed and 
common mental disorders, and that there 
is no evidence for superiority of either CBT 
or STPP (Abbas, 2002, 2006; Abbas et al, 
2006; Cuijpers et al, 2008; Knekt et al, 
2004, 2008a, 2008b; Leichsenring, 2005; 
Leichsenring et al, 2004), but then excludes 
them from consideration because they do 
not deal with pure depression. A further 
government sponsored systematic review of 
brief psychotherapy for depression that also 
found no evidence of superiority (Churchill 
et al, 2001) was not included. 
However looking at ‘common mental 
disorders’ has greater validity and gives 
a better indication of effectiveness than 
studies with high homogeneity but which 
do not reflect the complexity of patients 
encountered in primary let alone secondary 
care. (Leichsenring, 2004; Black, 1996; 
Geddes, 2009; Bagshaw & Bellomo, 2008; 
Grossman & MacKenzie, 2005; Blair, 2004).
9We note inconsistency in that the 
guideline includes health economic 
studies for computerised CBT in mixed 
anxiety and depression (NICE 2009c 
p158). This makes the decision to 
exclude such mixed studies from the 
clinical review in the case of dynamic 
therapies more questionable. 
The importance of patient 
preference and choice as 
opposed to imposition  
of stepped care 
Patient preferences and strength of 
preference have been shown to have a 
significant influence on whether patients 
take up treatment and complete it (Raue 
et al, 2009). Raue et al, (2009) argue on 
the basis of the importance of strong 
preferences that if a patient has a strong 
treatment preference they should be offered 
that treatment so as to reduce non-take up 
and discontinuation. 
The ‘stepped care’ model proposed 
is unproven as a method of providing 
psychological therapies, (Bower et al 2005). 
In practice stepped care does not appear to 
function well, at the Doncaster Improving 
Access to Psychological Therapies (IAPT) 
pilot site where the stepped care protocol 
was applied 47% of patients dropped out 
before the second appointment (Clark et 
al, 2008, p12-13). This will be discussed 
further below when considering the 
evaluation of IAPT. 
Individual factors – Tailoring treatment: The 
Guideline does not address the primary 
clinical goal of deriving a formulation 
explaining the predisposing, precipitating, 
perpetuating and protective factors that 
give rise to the form of depression in that 
individual patient and choosing treatment 
which reflects careful tailoring of treatment 
towards what is specific to the individual 
patient and the issues the patient feels are 
relevant. This cannot be addressed based 
on the restricted types of evidence admitted 
by the Guideline Development Group. 
These are commonplace diagnostic 
challenges for clinicians. The Guideline (p 8) 
stresses that guidelines are not a substitute 
for professional knowledge and clinical 
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judgement.  However, the political reality is 
that they do shape management practice in 
a way that often precludes the application 
of clinical judgement (e.g., in determining 
what treatments are not available – see 
IAPT below).  
The guideline limits patient choice 
by offering only restricted options; 
antidepressant drugs or CBT, IPT, or possibly 
behavioural couples therapy and that 
psychodynamic psychotherapy should only 
be available after ‘failing’ or refusing other 
treatments. This is not evidence based or 
respectful of patient choice. 
Limitations of a short-term  
perspective on a chronic disorder
Short-term trials for a chronic disorder: The 
guideline recognises that  ‘Less than half of 
treated patients achieved full remission and 
sustain it over a period of 2 years following 
treatment’ (p142). However the majority of 
studies reviewed only have short follow up 
periods, which give little indication as to 
how the treatment may affect relapse rates. 
The range of follow up periods among the 
trials of CBT ranged from 2 months to 24 
months. Among the trials of STPP the range 
was 3 months to 48 months.
The guideline states that ‘for patients 
in remission who did not relapse during 
follow-up, it was assumed that no further 
additional treatment or mental health care 
resources beyond the 6-month maintenance 
period were required’ (p232). This lacks 
credibility given the long-term and relapsing 
nature of depression after short-term 
treatments.
This reliance on short term trials resulted 
in the economic analyses being based on 
only six months of follow up: when cost 
modelling ‘a time horizon of 15 months was 
chosen to reflect the available comparative 
clinical evidence. This included 3 months 
of the initial therapy, followed by 6 months 
maintenance therapy and 6 months follow-
up’ (p230). It is questionable how useful 
this short-term analysis is in evaluating 
treatments of a long-term disorder. 
Other research confirms the need to take 
a long-term perspective on depression: In 
clinically significant depression the natural 
course of the condition is often prolonged, 
relapsing or recurrent (Surtees & Barkley, 
1994). After a first episode of depression 
only 50% remain free from depression over 
23 years of follow up. The figure would be 
lower if it included cases with recurrent 
depression (Eaton et al, 2008). Ninety 
11
percent of people having three episodes 
of depression will experience recurrences 
(Gelder et al, 2001). At one year follow-up 
about 60% of those treated with drugs still 
meet criteria for caseness (Goldberg et al, 
1998). 
Some evidence exists which suggests 
that in the longer term psychodynamic 
psychotherapies may lead to late 
improvements; e.g. Snyder et al, (1991) 
found large differences in four-year follow-
up data regarding marital status and marital 
accord for 59 couples receiving either 
behavioural (BMT) or insight-oriented 
(IOMT) marital therapy in a controlled 
outcome study. Although no significant 
group differences had been observed 
between the 2 treatment conditions at 
either termination or 6-month follow-up, 
by 4-year follow-up a significantly higher 
percentage of BMT couples had experienced 
divorce (38% for BMT couples compared 
with 3% for IOMT couples).
Erosion of benefits of CBT: Recent 
government-sponsored research into 
the long-term effects of CBT used in 
the treatment of anxiety found that the 
positive effects of CBT identified in the 
original trials were eroded over a period 
of two years. No evidence was found for 
an association between more intensive 
therapy and more enduring effects of CBT. 
The cost-effectiveness analysis showed no 
advantages of CBT over non-CBT (Durham et 
al, 2005).
Short-term psychotherapies have large 
effect sizes in the short term, comparable to 
or greater than medication, and depressed 
individuals treated with short-term 
psychotherapy are likely to ‘recover’ from 
depression after receiving psychotherapy. 
However even after receiving short-term 
psychotherapy for depression, individuals 
still have considerably lower mood and 
considerably more depressive symptoms 
than does the general population. Robinson 
et al (1990) compared studies of short-term 
psychotherapy for depression and found 
that before treatment depressed subjects 
scored on average 21.8 on the Beck 
Depression Inventory (BDI), after treatment 
the average BDI score was 11.8, however 
in the general population (matched for age 
and gender) the mean BDI score was 7.0, 
and in the population free of mental health 
difficulties the mean BDI score was 4.9. 
Long Term Psychotherapy: Given that 
depression is recurrent or chronic in the 
majority of individuals and the limitations 
of short-term treatments it is surprising that 
there is no consideration in the guideline 
of the role of long term psychotherapy. 
Especially given that there is a considerable 
evidence base for long term psychotherapy.
Short-term psychotherapy is sufficiently 
effective for most subjects suffering 
from acute distress, but insufficient for a 
considerable proportion of patients with 
chronic mental disorders or personality 
disorders. According to Kopta et al (1994), 
(p.1014, Figure 2), about 70% of the 
patients with acute distress were rated as 
clinically significantly improved after 25 
sessions. For patients with chronic distress, 
this was true for about 60%. However, for 
patients with characterological distress, 
i.e., personality disorders, the same 
data suggest that after 25 sessions only 
slightly more than 40% of the patients 
are clinically significantly improved. More 
than 52 sessions are required for about 
50% of these patients to be clinically 
significantly improved. Perry et al (1999) 
estimated the length of treatment necessary 
for patients with personality disorder 
to no longer meet the full criteria for a 
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personality disorder (recovery). According 
to these estimates, 50% of patients with 
personality disorder would recover by 
1.3 years or 92 sessions, and 75% by 2.2 
years or about 216 sessions (Perry et al, 
8, p. 1318). According to these data, the 
majority of patients with acute distress 
benefit significantly from short-term 
psychotherapy, whereas for patients with 
chronic distress and personality disorders, 
short-term psychotherapy is not sufficient. 
This is true of psychodynamic therapy, and 
of psychotherapeutic approaches that are 
usually short-term, such as CBT (Linehan et 
al, 2006; Linehan et al, 1994; Giesen-Bloo 
et al, 2006). 
There is good evidence that long term 
psychodynamic psychotherapy has superior 
results to short term psychotherapy in 
patients with complex, or co-morbid 
disorders. These results are clinically 
and statistically significant, both in RCTs 
(Leichsenring & Rabung, 2008) (Knekt 
et al, 2008) and observational studies 
(Knekt et al. 2004, 2008a, 2008b; de 
Maat et al, 2009) with no difference 
between observational studies and RCTs 
(Leichsenring & Rabung, 2009). Long-term 
psychodynamic psychotherapy produces 
enduring changes in personality functioning 
(Bond & Perry, 2004; de Maat et al, 2009; 
Fonagy, 1999; Clarkin et al, 2007). It is 
regrettable the updated guideline has 
dropped a previous recommendation for 
consideration of long-term psychodynamic 
psychotherapy, and risks removing 
provision for those patients who may need 
this treatment, as well as unjustifiably 
restricting patient choice. 
The need to consider effectiveness 
and observational trials alongside 
RCTs and efficacy trials
Randomised Control Trials and 
observational studies: ‘RCTs are simply  
experimental tools used to test hypotheses 
— they are not well designed to assess 
clinical effectiveness’ (McAllister-Williams, 
2008, p67). RCTs face particular problems 
in assessing complex interventions where 
there may be multiple ‘active ingredients’ and 
patient preferences may influence outcome 
(MRC, 2000). It is widely disputed that RCTs 
represent the highest form of evidence for 
psychotherapy. In psychotherapy particularly 
randomisation may reduce the validity of the 
intervention. Naturalistic studies may be a more 
valid means of assessing the effectiveness of 
psychotherapy in the real world (Leichsenring, 
2004). Randomized clinical trials test a 
somewhat artificial treatment in an artificially 
controlled setting with atypical patients, so 
they have reduced generalisability to the real 
world of mental health care delivery (Ablon 
& Jones, 2002; Bagshaw & Bellomo, 2008; 
Black, 1996; Blair, 2004; Geddes, 2009; 
Grossman & MacKenzie, 2005). 
The guideline development group would 
do well to heed the advice of NICE’s own 
chair Michael Rawlins, who has criticised 
the ‘undeserved pedestal’ that RCTs occupy 
(Rawlins, 2009) and quotes Bradford Hill, 
the architect of the RCT: ‘Any belief that the 
controlled trial is the only way would mean 
not that the pendulum had swung too far but 
that it had come right off the hook’ (Hill, 1965).
RCTs test what happens at the level of 
populations, not individuals. They are based 
on a statistical abstraction of what happens 
in the ‘population’ with that diagnosis. RCTs 
only apply to individuals in a probabilistic 
way, that is in so far as one can extrapolate 
from the hypothetical statistical population 
to the concrete individual with his or her 
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idiosyncrasies and individual history. 
Individuals all differ from the population 
mean, and therefore respond differently 
from the ‘average’ (McQueen, 2009).
CBT, IPT and psychodynamic psychotherapy 
have all already proved their efficacy in RCTs. 
It is therefore appropriate that the guideline 
consider effectiveness and naturalistic studies 
to assess how well these psychotherapies 
function in the real world of NHS practice, with 
patients who in the majority have complex 
and co-morbid conditions.
In any case it has been shown empirically 
that high quality observational studies 
which use observational control groups do 
not systematically differ to RCTs in general 
medical conditions (Concato et al, 2000) 
and in trials of long-term psychotherapy 
(Leichsenring & Rabung, 2009).
Both CBT and STPP have demonstrated 
efficacy in RCTs as reviewed in the draft Full 
Guidance, however once efficacy is proven 
evidence of effectiveness is required. Several 
reviews that confirm the effectiveness of 
STPP in RCTs in real world mixed settings 
exist (Abbas, 2002; Abbas, 2006; Abbas 
et al, 2006; Cuijpers et al, 2008; Knekt et 
al, 2004, 2008a, 2008b; Leichsenring, 
2005; Leichsenring et al, 2004). However 
they were excluded because of their 
clinical heterogeneity (NICE 2009a, p145-
146), precisely the attribute required for 
establishing effectiveness in the real world. 
The results of two (non randomised) 
observational outcomes studies of 
psychotherapy in the real world of the NHS, 
highly relevant for this guideline, and again 
showing similar effectiveness of different 
short-term psychotherapies, were not 
included (Stiles et al 2006, 2008).
Other issues
Use of the term evidence based: Section 
6.1.2 states that ‘for a therapy to become 
evidence based it typically passes through 
several phases of treatment development’ 
and then goes on to argue, via an hourglass 
metaphor, a set of normative stages in the 
development of a new treatment (p125). 
Whilst this may describe some aspects 
of the development of CBT, there is no 
scientific justification for this prescription. It 
is unscientific and misleading to assert that 
only treatments that have evolved through 
these stages are evidence based. Any 
treatment that has evidence of effectiveness 
is, in a straightforward sense, evidence 
based, even if some of the mechanisms of 
the treatment remain obscure or debated. 
This is the case for many pharmacological 
treatments and physical treatments such 
as ECT. Indeed this is also the case for CBT; 
see for example Jones et al, (1993).
The repeated labelling of CBT as evidence 
based and psychodynamic psychotherapy 
as not is unscientific, devalues the meaning 
of the terms and amounts to little more than 
spin.
Branding of psychotherapies: There is no 
discussion of the empirical separation of 
the different ‘brands’ of psychotherapy 
compared in the guideline, which has 
been shown to be limited (Ablon & Jones, 
1998). Specifically there is no mention of 
the important work of the NIMH treatment 
of depression collaborative research 
program demonstrating ‘that cognitive 
behavior [sic] therapists occasionally used 
psychodynamic strategies and that it was 
these techniques that were responsible 
for promoting patient change’ (Jones et al, 
1993) and that relying on brand names 
of therapy can be misleading and that 
patient in-session characteristics were far 
more important correlates of outcome than 
treatment type (Ablon & Jones, 2002). 
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Health Economic Evidence review and 
considerations: The restriction to only 
consider studies of cost effectiveness 
conducted in the UK is scientifically 
unjustified, overly restrictive and leads to 
the exclusion of many important studies 
e.g. Abbas (2002, 2003, 2006).
Improving Access to  
Psychological Therapies
There is a close relationship between 
the NICE guidance on depression, with 
its enthusiastic endorsement of CBT 
and the IAPT initiative. IAPT evolved out 
of The depression report: A new deal 
for depression and anxiety disorders 
(Centre for Economic Performance, 2006), 
sometimes referred to the Layard report, 
after its principle author, the economist 
Richard Layard. It is important to note, 
however, IAPT is intended to be an evolving 
programme. 
The economic rationale behind the 
depression report was to get people on 
long-term sickness benefits with depression 
and anxiety off benefits and back into 
work, through short courses of CBT. The 
Depression Report made ambitious claims 
for the efficacy of CBT in depression and 
anxiety: ‘The typical short-term success 
rate for CBT is about 50 per cent.’ And ‘After 
recovery, people who suffered from anxiety 
are unlikely to relapse.’ (p6) These claims 
need to be seen in the context of translating 
from trials to real world settings where 
epidemiological evidence tells us co-morbid 
presentations will prove to be the norm in 
IAPT.. The economic analysis advanced in 
the Depression Report was that treating 
those on sickness benefits for depression 
and anxiety with CBT would lead to some of 
those numbers returning to work so that the 
cost of the service would be ‘fully offset, of 
course, by rapid savings to the Department 
of Work and Pensions and HM Revenue & 
Customs.’ (p11) 
A stated aim of IAPT is to implement NICE 
guidance for depression (and anxiety). It 
is therefore relevant to consider briefly the 
results of the Initial Evaluation of the Two 
Demonstration Sites for the pilot phase CBT 
service models for IAPT (Clark et al, 2008).  
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At Doncaster GPs were asked to refer 
patients with at least moderate depression 
‘except those with a history of repeated 
treatment failure, psychotic features, 
personality disorder, primary drug/alcohol 
problems, or significant risk.’ And ‘all 
patients with GAD [generalised anxiety 
disorder] panic disorder (with or without 
agoraphobia), simple phobias, social 
phobia, and health anxiety, except those 
with significant suicide risk or who have 
failed to respond to at least 3 interventions’ 
(p5). 
It was found that 47% dropped out before 
the second session (p12-13). Fifty three 
percent were described as ‘treated’ after 2 
or more sessions, however the methodology 
(in NICE’s terms) is of poor quality, ignoring 
those who drop out of treatment (it is a 
‘survivor analysis’ and is therefore biased 
toward selecting good outcomes and 
inflating effect sizes) there is no intention 
to treat or sensitivity analyses, and as such 
the results may be not be attributable to 
the effect of the interventions, rather they 
may be  a result of drop out. The tools used 
for diagnosis and monitoring therapy (the 
nine item Patient Health Questionnaire 
(PHQ) and seven item Generalized 
Anxiety Disorder Questionnaire (GAD)) 
are screening tools, neither are designed 
or validated as diagnostic tools or for 
measuring treatment response, which limits 
comparability of outcomes.
NICE recommendations for the stepped 
care management of depression indicate 
that patients who fail to respond at step 
2 care should be offered a move to step 3 
where ‘CBT is the psychological treatment of 
choice’ but therapists could also ‘consider 
interpersonal psychotherapy (IPT) if the 
patient expresses a preference for it or 
you think the patient may benefit from it’. 
Interpersonal therapy was not available 
in Doncaster IAPT so there was no choice. 
Of the 1603 that had any of the step 2 
interventions, 34 also had step 3 CBT, while 
1569 did not. This gives a step-up rate of 
2.1%. There is no investigation of why 98% 
did not progress to individual CBT, but it 
is possible that some of these patients 
may have been disaffected by what they 
received and disengaged. If so, it represents 
a wasted opportunity.  
It is reported that out of the 4451 referrals 
to the Doncaster IAPT over 13 months 66 
people per month were referred on to the 
various PCT counselling services (p.16). 
This gives a referral rate to counselling 
of 19% (13x66/4451).  It is interesting 
to compare the step up rate of 2.1% to 
stage 3 CBT at Doncaster with the 19% of 
referred patients who were referred on to 
PCT counselling services. Although it is 
recognised that referral on to counselling is 
a form of stepping-up, albeit one outside of 
the stepped care protocol recommended by 
NICE, the figures for referrals to counselling 
are not presented as part of the overall 
step-up rate. These figures suggest that 
step 3 CBT may be less well suited to the 
needs of the patients referred to IAPT than 
counselling provided through the PCT 
counselling services.
Psychological outcomes at Doncaster were 
based on verbal answers to the GAD and 
PHQ at the start of each session given to the 
case manager. Based on this the authors 
concluded that 56% had recovered by the 
time they left the system. It is important 
to note that this is a post treatment 
assessment and a survivor analysis and is 
therefore biased toward good outcomes.
A follow up survey was conducted at three 
months after the end of treatment. The 
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response rate was low at 51%. The authors 
claim that 50% were still ‘recovered’, but 
given the low response rate this figure 
must be treated with caution. At follow up 
employment figures showed a net increase 
in benefit receipts of 2.4%. There was an 
increase of numbers going to work of only 
1 person (out of 452 responders) that was 
matched by a reduction of one among those 
receiving statutory sick pay (SSP). The total 
number with jobs (i.e. employed whether or 
not on SSP) remained constant. Again it is 
worth noting that this is a ‘survivor analysis’ 
and may inflate good outcomes, which 2nd-
phase IAPT services might then struggle to 
replicate. 
The Newham site differed in that it saw a 
broader range of common mental health 
conditions and the data was presented 
differently. Here 33% dropped out before the 
second session. Nonetheless it is claimed 
based on answers given by patients to their 
case managers on the PHQ and GAD that 55% 
had recovered after two or more sessions. 
Among people who concluded treatment 
and attended 2 or more sessions, the net 
increase of people at work corresponded 
to 10% of the treated population. This 
increase came mainly from reducing 
numbers receiving Statutory Sick Pay 
(a decrease of 6%), and a decrease in 
numbers in the ‘other’ category (not 
employed, and not receiving benefits or 
SSP) of 4%. However this was pre to post 
treatment, not to follow up, looking at 
the figures differently SSP fell from 10 to 
2 post treatment, out of 72 with jobs pre 
treatment. The number with jobs (SSP and 
at work) rose from 67 to 72 = 5/135 =3.7%. 
However given that 33% dropped out, these 
results also need to be treated cautiously.
The response rate to the three-month 
follow up study at Newham was 36% (60 
responses), which is very low. At follow 
up the authors claim that 42% remained 
‘recovered’, however given the very low 
response rate it is difficult to attach 
meaning to this. With regard to employment 
in the follow-up survey, there was a net 
increase in numbers employed of three. The 
net drop in benefit receipt was one. There 
was a net increase in numbers receiving 
Statutory Sick Pay of two. Again the results 
should not be attributed to the effects of 
the interventions without caution as a result 
of drop out and the low response rate. 
It is too early to say whether IAPT is going 
to fulfil the expectations set out in the 
Depression Report. The challenges outlined 
above illustrate the difference between 
efficacy studies, as used in the Depression 
Report, and effectiveness studies such as 
the review of the outcomes from the IAPT 
pilot sites. 
IAPT will be most likely to meet these 
challenges and achieve good outcomes 
if it can gain widespread support among 
psychotherapy practitioners. But the 
perception, at least, amongst many non-CBT 
practitioners, and some CBT practitioners, 
is that NICE and IAPT are combining 
to systematically devalue all other 
approaches.
The risks presented by uncritical 
enthusiasm of proponents of CBT and/
or IAPT have led to concern among 
practitioners of CBT themselves. Writing in 
The Psychologist, Marzillier and Hall (2009) 
respond to IAPT: 
‘there is one major drawback – it won’t 
work.’ ‘when the dust settles and it is 
realised that CBT is not the panacea it 
has been made out to be, there may well 
be a backlash against all psychological 
therapies.’ ‘Those with mild to moderate 
problems are the ones who will respond 
best to CBT or a similar therapy. Only a 
minority of those with more serious and 
complex problems – who are likely to be 
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those on long-term incapacity benefit – 
will benefit from that approach alone, 
and many will need something different 
from short-term, specific treatments 
designed to alleviate symptoms.’ ‘What 
concerns us with the Layard analysis is 
the way this complexity has been glossed 
over to arrive at general conclusions 
that seem superficially plausible but in 
reality are not. The attraction may be 
that at last the value of psychological 
therapy is recognised and serious money 
made available for it. But if the basis for 
this expansion is flawed, there will be 
trouble ahead. If the equations do not 
work, there may well be a backlash as the 
new breed of psychological therapists 
fails to deliver what it promises and the 
cost savings predicted by Layard do 
not materialise.’ ‘The worry of the IAPT 
programmes is that people are being 
trained to work in one particular way 
(as CBT therapists) with the result that 
managers think this is the only way. Put 
crudely, the message is that most mental 
health problems will be ‘solved’ if we 
train enough [CBT] therapists. This should 
be exposed for the nonsense it is.’ ‘We 
reject the one-size-fits-all, techniques-
driven approach in favour of the virtues of 
initial psychological assessment, careful 
formulation and offering patients a range 
of options, amongst which therapy, CBT 
or otherwise, is just one.’
It is worth quoting these not to fuel concern 
or take sides in the argument, since any 
judgements about IAPT are premature, but 
to draw attention to increased risks from 
mutually reinforcing assumptions in the 
NICE guideline. If assumed superiority of 
CBT, not supported by evidence, were to 
prevent redesign or experiment with second 
and third phase IAPT models, this would 
stifle further development and innovation. 
Summary and conclusion
The revision of the NICE guideline 
on the treatment of depression is to 
be welcomed for making clear the 
complex nature of depression and its 
importance. It rightly highlights the central 
importance of psychological therapies 
in the treatment of depressive disorders 
and their effectiveness. However the 
guideline limits its utility to patients and 
clinicians by restricting itself to a narrow, 
undifferentiated and simplistic conception 
of depression. It also unhelpfully restricts 
itself purely to randomised controlled 
trials, and excludes naturalistic trials 
despite their clear advantages in 
assessing psychotherapeutic treatments 
and treatments in the real world. The 
evidence for the lasting effects of long-
term psychotherapy in depression is not 
reviewed despite the mass of evidence 
presented that depression is frequently 
chronic or recurring and the evidence of 
the limited effect of short-term treatments. 
Furthermore the economic analyses are 
based entirely on short-term models. There 
is insufficient consideration of importance 
of individual patient preferences or 
different types or aetiologies of depression, 
leading to restrictive one-size-fits-all 
recommendations, with attendant 
implementation risks.
The 2004 NICE guidelines for depression 
and 2004 NICE guidelines for anxiety with 
their recommendations for CBT contributed 
in part to the development of the 
Depression Report and Improving Access 
to Psychological Therapies. The first-phase 
IAPT model has not yet been shown to be 
any more effective or acceptable to patients 
in the real world than existing services but 
NICE’s new guidance risks reinforcing an 
untested assumption, stifling improved 
patient care and restricting patient 
choice through overly-crude or coercive 
implementation.
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Notwithstanding this, the evidence 
presented, in keeping with the bulk of the 
scientific literature, finds ‘no clinically 
important differences’ between Cognitive 
Behavioural Therapy, Interpersonal 
Psychotherapy, Short Term Psychodynamic 
Psychotherapy and Brief Supportive 
Counselling. Having excluded much 
evidence for the effectiveness of STPP 
and Counselling the 2009 guideline 
recommends CBT and IPT as its preferred 
treatment options on the basis, not of 
superiority, but on the fact that there were 
more trials demonstrating efficacy. In 
principle, then, this leaves an open door for 
IAPT to evolve and test a broader range of 
service models. 
One should ask what sort of evidence 
would be necessary to reliably conclude 
that one form of psychotherapy is superior 
to another. The answer should include 
replicated studies, consistently showing 
a clinically relevant advantage of one 
treatment over another, long follow-up 
periods, different methodologies, and data 
showing effectiveness in real world settings. 
The data we have currently, including from 
IAPT, points strongly against any reliable 
conclusion favouring CBT or IPT over other 
therapies. 
We have few studies by research groups 
demonstrating equipoise (for an exception 
see Stiles et al 2008). Investigator 
allegiance, the motivation of research 
groups to ‘prove’ their own brand of therapy 
to be best, has been shown to introduce 
large biases (Luborsky et al. 1999). 
By wording recommendations in a way, 
which may be misinterpreted as showing 
CBT and IPT are superior ‘evidence-based’ 
treatments, NICE risks devaluing science, 
as well as undermining the credibility of its 
guideline.
Patients with depression treated with 
CBT or IPT often have positive but 
limited initial responses followed by 
high rates of recurrence. It is essential, 
and in the interest of patients, that all 
treatment options for depression are fully 
explored. Indications are that longer-term 
psychodynamic psychotherapy may have 
superior and more lasting effects for some 
patients. There is an urgent need for well-
funded trials to explore if those who do not 
respond to CBT can benefit from other forms 
of treatment including psychodynamic 
psychotherapy and the extent to which long-
term treatments have superior outcomes in 
the medium or long-term.
There is a need for future NICE guidelines 
that are adapted to the differing types and 
aetiologies of depression and the differing 
priorities of individual patients. They 
should cover long-term psychotherapies 
and consider the range of types of evidence 
required to assess the effectiveness of 
psychotherapy in the real world. It is 
essential that guidelines are based on 
systematic reviews of the evidence and 
not simple counting of trials. They should 
impartially present the evidence as it is. 
It remains to be seen what the published 
guideline will say and, more importantly 
perhaps, how IAPT evolves its 2nd and 3rd 
phase service models to continue the task 
both of implementing NICE’s guidelines 
and achieving good outcomes for all IAPT’s 
patients – including the 50% who fail 
to recover having had NICE’s preferred 
treatments.  
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